Satsuma Pharmaceuticals, Inc. (STSA) Daily Stock Prediction

Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops a novel therapeutic product for the acute treatment of migraine. Its lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in Phase III clinical trials and can be self-administered with a proprietary pre-filled, single-use, and nasal delivery device. The company was founded in 2016 and is headquartered in South San Francisco, California.

Sector:

Healthcare

Industry:

Biotechnology

Employees:

20

Address:

Satsuma Pharmaceuticals, Inc. 400 Oyster Point Boulevard Suite 221 South San Francisco CA 94080 United States

Website:

Home

Phone:

650-410-3200